Table 3 Characteristics of patients treated with nivolumab in responder and non-responder groups
Variables | Responder (n = 21) | Non-responder (n = 37) | p |
|---|---|---|---|
No. (%) | No. (%) | ||
Sex | |||
 Male | 18 (86%) | 27 (73%) | 0.338 |
 Female | 3 (14%) | 10 (27%) | |
Age (years) (Median, Range) | 66 (53–76) | 66 (38–82) | 0.581 |
ECOG performance status | |||
 0 | 6 (29%) | 2 (5%) | 0.021 |
  ≥ 1 | 15 (71%) | 35 (95%) | |
Disease status | |||
 Metastatic | 16 (76%) | 27 (73%) | 1 |
 Relapsed | 5 (24%) | 10 (27%) | |
Primary site | |||
 Gastric | 17 (81%) | 32 (87%) | 0.71 |
 Esophagogastric junction | 4 (19%) | 5 (14%) | |
Histological type | |||
 Intestinal type | 12 (57%) | 22 (60%) | 1 |
 Diffuse type | 9 (43%) | 15 (40%) | |
HER-2 status | |||
 Positive | 2 (10%) | 11 (30%) | 0.106 |
Site of metastases | |||
 Lymph nodes | 13 (62%) | 28 (76%) | 0.369 |
 Hematogenous | 9 (43%) | 24 (65%) | 0.167 |
 Peritoneum | 12 (57%) | 15 (41%) | 0.278 |
Organs with metastasis | |||
 1 | 11 (52%) | 6 (16%) | 0.006 |
  ≥ 2 | 10 (48%) | 31 (84%) | |
Previous treatment regimens | |||
 2 | 14 (67%) | 21 (57%) | 0.704 |
 3 | 5 (24%) | 13 (35%) | |
  ≥ 4 | 2 (9%) | 3 (8%) | |
Previous therapies | |||
 Pyrimidine analogs | 20 (95%) | 36 (97%) | 1 |
 Platinum | 18 (86%) | 32 (87%) | 1 |
 Taxane | 20 (95%) | 35 (95%) | 1 |
 Ramucirumab | 16 (76%) | 32 (87%) | 0.471 |
 Trastuzumab | 2 (10%) | 9 (24%) | 0.296 |
 Irinotecan | 5 (24%) | 11 (30%) | 0.764 |
Treatment period before nivolumab (months) | 17.3 (8.1–37.1) | 14.6 (4.9–64.6) | 0.225 |
Immune-related adverse events | |||
 Positive | 7 (33%) | 3 (8%) | 0.027 |